Clinical Trial Results:
A Phase IIIB multicenter, double-blind, randomized, placebocontrolled study, evaluating the effect of treatment with dalcetrapib 600 mg on Atherosclerotic Disease as measured by I. Coronary Intravascular Ultrasound (IVUS), Quantitative Coronary Angiography II, Carotid B-Mode Ultrasound Intima Medial Thickness (IMT) and total plaque volume in subjects undergoing coronary angiography who have coronary artery disease (CAD).
Summary
|
|
EudraCT number |
2009-017725-19 |
Trial protocol |
DE |
Global completion date |
23 Sep 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
03 Jun 2016
|
First version publication date |
03 Jun 2016
|
Other versions |
|
Summary report(s) |
Redacted CSR Synopsis - NC22703 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.